133 related articles for article (PubMed ID: 4039984)
41. Clinical and pharmacokinetic overview of parenteral etoposide phosphate.
Schacter LP; Igwemezie LN; Seyedsadr M; Morgenthien E; Randolph J; Albert E; Santabárbara P
Cancer Chemother Pharmacol; 1994; 34 Suppl():S58-63. PubMed ID: 8070028
[TBL] [Abstract][Full Text] [Related]
42. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin.
Relling MV; McLeod HL; Bowman LC; Santana VM
Clin Pharmacol Ther; 1994 Nov; 56(5):503-11. PubMed ID: 7955814
[TBL] [Abstract][Full Text] [Related]
43. Hyperglycosylated hCG in gestational implantation and in choriocarcinoma and testicular germ cell malignancy tumorigenesis.
Cole LA; Khanlian SA; Riley JM; Butler SA
J Reprod Med; 2006 Nov; 51(11):919-29. PubMed ID: 17165440
[TBL] [Abstract][Full Text] [Related]
44. Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B.
Nissen NI; Pajak TF; Leone LA; Bloomfield CD; Kennedy BJ; Ellison RR; Silver RT; Weiss RB; Cuttner J; Falkson G; Kung F; Bergevin PR; Holland JF
Cancer; 1980 Jan; 45(2):232-5. PubMed ID: 6985831
[TBL] [Abstract][Full Text] [Related]
45. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide.
Minami H; Ando Y; Sakai S; Shimokata K
J Clin Oncol; 1995 Jan; 13(1):191-9. PubMed ID: 7799020
[TBL] [Abstract][Full Text] [Related]
46. High-dose etoposide (VP-16) in small-cell lung cancer.
Greco FA; Johnson DH; Hande KR; Porter LL; Hainsworth JD; Wolff SN
Semin Oncol; 1985 Mar; 12(1 Suppl 2):42-4. PubMed ID: 2983434
[TBL] [Abstract][Full Text] [Related]
47. Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.
Anderson G; Payne H
Semin Oncol; 1985 Mar; 12(1 Suppl 2):21-2. PubMed ID: 3883504
[TBL] [Abstract][Full Text] [Related]
48. [Effects of etoposide in testicular tumors].
Tanahashi T; Matsumura Y; Ozaki Y; Yoshimoto J; Tsushima T; Obama T; Akagi T; Nasu Y; Ohmori H
Gan To Kagaku Ryoho; 1986 Oct; 13(10):3074-7. PubMed ID: 3767390
[TBL] [Abstract][Full Text] [Related]
49. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
[TBL] [Abstract][Full Text] [Related]
50. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.
Lowis SP; Pearson AD; Newell DR; Cole M
Cancer Res; 1993 Oct; 53(20):4881-9. PubMed ID: 8402676
[TBL] [Abstract][Full Text] [Related]
51. The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.
Roed H; Vindelov LL; Christensen IJ; Spang-Thomsen M; Hansen HH
Cancer Chemother Pharmacol; 1987; 19(1):16-20. PubMed ID: 3815721
[TBL] [Abstract][Full Text] [Related]
52. [Experiences with VP-16 in combination with cyclophosphamide or adriamycin in the anaplastic, predominantly small cell bronchogenic carcinoma].
Schmieder HA; Jungi WF; Mayr AC; Senn HJ
Schweiz Med Wochenschr; 1979 Jun; 109(22):841-4. PubMed ID: 462156
[TBL] [Abstract][Full Text] [Related]
53. Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study.
Thompson DS; Hainsworth JD; Hande KR; Holzmer M; Greco FA
Cancer; 1994 Jun; 73(11):2824-31. PubMed ID: 8194024
[TBL] [Abstract][Full Text] [Related]
54. Predicting etoposide toxicity: relationship to organ function and protein binding.
Joel SP; Shah R; Clark PI; Slevin ML
J Clin Oncol; 1996 Jan; 14(1):257-67. PubMed ID: 8558207
[TBL] [Abstract][Full Text] [Related]
55. [Successful collection of peripheral blood stem cells mobilized by high-dose etoposide for patients with chemotherapy-resistant and/or poor prognostic testicular cancer].
Nakagawa S; Sugimoto K; Mikami K; Watanabe H; Sonoda Y; Kuzuyama Y; Abe T; Fujii H
Nihon Hinyokika Gakkai Zasshi; 1994 Apr; 85(4):571-8. PubMed ID: 7514697
[TBL] [Abstract][Full Text] [Related]
56. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
[TBL] [Abstract][Full Text] [Related]
57. What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 days.
van der Gaast A; Vlastuin M; Kok TC; Splinter TA
Semin Oncol; 1992 Dec; 19(6 Suppl 14):8-12. PubMed ID: 1488657
[TBL] [Abstract][Full Text] [Related]
58. [Etoposide. A new highly effective cytostatic agent in anaplastic small-cell bronchial carcinoma, other solid tumors and hemoblastoses].
Goldhirsch A; Joss R; Cavalli F; Sonntag RW; Ryssel HJ; Brunner KW
Dtsch Med Wochenschr; 1981 Aug; 106(35):1105-9. PubMed ID: 6266800
[No Abstract] [Full Text] [Related]
59. [Pharmacokinetics of etoposide short-term infusions within the scope of the GPOH therapy protocol].
Boos J; Real E; Schulze-Westhoff P; Pröbsting B; Wolff J; Jürgens H
Klin Padiatr; 1993; 205(4):288-94. PubMed ID: 8377449
[TBL] [Abstract][Full Text] [Related]
60. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.
Wolff SN; Fer MF; McKay CM; Hande KR; Hainsworth JD; Greco FA
J Clin Oncol; 1983 Nov; 1(11):701-5. PubMed ID: 6366131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
